ClinicalTrials.gg
RecruitingNCT07444814Updated Aug 5, 2026

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

A Phase 1 interventional study of HWK-007 in Endometrial Cancer, Ovarian Cancer and Ovarian Cancer Metastatic, sponsored by Whitehawk Therapeutics, Inc.. Recruiting at 12 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-05.

Sponsored by Whitehawk Therapeutics, Inc. · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Started Dec 2025; still recruiting 10 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
226
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 715 studies in Endometrial Neoplasms with a site in United States — 197 open to participants now, 286 under way, 22 of them phase 3. Endometrial Neoplasms · United States.

Planned enrollment
126th of 591
226 · median 60
Started
2025
with 54 others
Phase 1
192 of 715
50 open now
Primary completion
2028-10
later than 213 of 285 live
Registered
683rd of 715
by date

Among the 715 studies in Endometrial Neoplasms with a site in United States, this one is the 126th largest by planned enrollment of the 591 interventional ones that give a count, is one of 55 that started in 2025, is one of 192 in phase 1, reaches primary completion later than 213 of the 285 other live ones, and was the 683rd registered.

Endometrial Neoplasms

1,428 studies on the registry are indexed under Endometrial Neoplasms; 472 are open to participants now.

Browse Endometrial Neoplasms studies →

Open to participants now

197 of the 715 studies in Endometrial Neoplasms with a site in United States are open now. Recruiting first, the newest first:

192 more — sign in →

All 197 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 356 Endometrial Neoplasms studies recruiting now, 266 (75%) set no upper age limit and 54 (15%) stop at 75 or younger; 26 take children under 18; 23 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 715 studies in Endometrial Neoplasms with a site in United States, or all of them as a file.
02

Study summary

HWK-007-101 is a multicenter, open-label, first-in-human (FIH) Phase 1 study evaluating HWK-007, a protein tyrosine kinase 7 (PTK7)-targeted antibody drug conjugate (ADC), in adult participants with advanced or metastatic solid tumors known to be expressing PTK7. The study employs a sequential dose escalation and dose expansion design without a control group.

Read the detailed description

The study consists of 2 phases, Phase 1a (dose escalation) and Phase 1b (dose expansion). In Phase 1a, participants with non-squamous Endothelial Growth Factor Receptor Wild type (EGFR Wt) NSCLC, platinum resistant ovarian cancer (PROC), and endometrial cancer will be enrolled. In Phase 1b, non-squamous EGFR Wt NSCLC expansion cohort(s) will be opened, based on the safety, tolerability, PK, and preliminary antitumor data in Phase 1a.

In Phase 1a of the study, HWK-007 will initially be administered as an intravenous (IV) infusion every 3 weeks (Q3W).

03

Conditions studied

  • Endometrial Cancer
  • Ovarian Cancer
  • Ovarian Cancer Metastatic
  • Ovarian Cancer Metastatic Recurrent
  • Non-squamous EGFR Wt NSCLC
  • Platinum Resistant Ovarian Cancer
  • PROC

Keywords

  • PTK7
  • Ovarian cancer
  • Endometrial cancer
  • NSCLC
  • Lung cancer
  • Chemotherapy
  • ADC
  • Antibody-Drug-Conjugate
  • Solid tumor
  • Phase 1
  • Ovarian neoplasms
  • Endometrial neoplasms
  • Carcinoma, Non Small Cell Lung
  • Lung neoplasms
  • Gynecologic cancer
  • EGFR Wt NSCLC
  • Platinum Resistant Ovarian Cancer
  • DNA Topoisomerase I
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Have one of the following solid tumor cancers:

  1. Monotherapy escalation and backfill cohorts:

    1. non-squamous EGFR-Wt NSCLC
    2. Endometrial carcinoma
    3. Platinum Resistant Ovarian Cancer
  2. Monotherapy expansion cohorts:

    1. Non-squamous EGFR-Wt NSCLC
    2. Additional tumor indications to be defined in a future amendment

Exclusion criteria

Exclusion Criteria:

  1. Individual with known or suspected uncontrolled central nervous system (CNS)
  2. Individual with history of carcinomatous meningitis
  3. Individual with active uncontrolled systemic bacterial, viral, fungal, or parasitic infection
  4. Individual with evidence of corneal keratopathy or history of cornea transplant
  5. Any serious unresolved toxicities from prior therapy
  6. Significant cardiovascular disease
  7. Prolongation of corrected for heart rate using Fridericia's formula (QTcF) ≥ 470 milliseconds (ms)
  8. History of pneumonitis/interstitial lung disease
  9. Individuals who are pregnant, breastfeeding or plan to breastfeed during study or within 30 days of last dose of study intervention
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
226 participants (estimated)

Study arms

  • Experimental
    Dose Escalation - 21 Day treatment cycle

    Escalating doses of HWK-007 administered intravenously (IV)

    Drug: HWK-007

  • Experimental
    Dose Expansion Group 1- 21-day treatment cycle - non-squamous EGFR-WT NSCLC

    Expanded enrolment at selected dose of HWK-007 in NSCLC.

    Drug: HWK-007

  • Experimental
    Dose Expansion Group 2 - 21-day treatment cycle - Tumor TBD

    Expanded enrolment at second selected dose of HWK-007 administered intravenously (IV) in Tumor - TBD

    Drug: HWK-007

  • Experimental
    Dose Expansion Group 3 - 21-day treatment cycle - Tumor TBD

    Expanded enrolment at third selected dose in Tumor - TBD

    Drug: HWK-007

  • Experimental
    Dose Expansion Group 4 - 21-day treatment cycle - Tumor TBD

    Dose Expansion of HWK-007, a PTK7-directed ADC.

    Drug: HWK-007

Interventions

  • DrugHWK-007

    HWK-007 is a PTK7- targeted ADC being developed for the treatment of solid tumors.

    Also known as: HWK-007 anti-PTK7 targeted ADC

06

What researchers measure

Primary outcomes

  1. Determine Maximum Tolerated Dose (MTD)

    Determine the highest dose of HWK-007 that can be administered without signs of toxicity measured at the end of Cycle 1 (21 day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE).

    Time frame: From Cycle 1, Day 1 until Cycle 1, Day 21 (21-day cycles)

  2. Determine Maximum Administered Dose (MAD)

    Determine the highest dose administered during the dose escalation part of the study measured at the end of Cycle 1 (21 day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE).

    Time frame: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles) until the MTD is reached.

  3. Determine the Recommended Dose for Expansion (RDE)

    Determine the dose that will be recommended for further study within the tumor types studied in this clinical trial measured at the end of Cycle 1 (21 day cycle) by: Incidence and severity of Adverse Events (AE). Incidence of Dose-Limiting Toxicities (DLT). Incidence of Serious Adverse Events (SAE).

    Time frame: From Cycle 1, Day 1 to Cycle 1, Day 21 (21-day cycles) until MTD is identified.

Secondary outcomes

  1. Characterize the Volume of Distribution (Vd) of HWK-007 (ADC, total antibody, CPT116, and CPT119)

    Pharmacokinetic analysis of HWK-007 in human subjects

    Time frame: Cycle 1 and Cycle 4 (21-day cycles)

  2. Assess ADA (Anti drug antibody) against HWK-007

    Using a blood test, determine the risk of developing anti-drug antibodies against HWK-007 following infusion in human patients.

    Time frame: Every cycle from Cycle 1, Day 1 (21-day cycles) until 30 days past the last dose of study drug for up to 24 months.

  3. Evaluate the Overall Response Rate (ORR)

    Measure the response rate to the study drug by CT-scans evaluated using RECIST1.1

    Time frame: From Cycle 1, Day 1 (21-day cycles), every 6-weeks for the first 4 assessments and then every 6 weeks for up to 24 months until disease progression or 24 months, whichever comes first.

  4. Evaluate Overall Survival (OS).

    Measure how long patient lives following treatment with HWK-007

    Time frame: From Cycle 1, Day 1 (21-day cycles) until death or 24 months, whichever comes first.

  5. Maximum Concentration - Cmax of HWK-007 (ADC, total antibody, CPT116, and CPT119)

    Maximum amount of study drug and drug components in blood following infusion.

    Time frame: At Cycle 1 and Cycle 4 - (21-day cycles)

  6. Time to Maximum Concentration (Tmax) of HWK-007 (ADC, total antibody, CPT116, and CPT119)

    Time to reach maximum concentration of drug and drug components in blood following infusion.

    Time frame: At Cycle 1 and Cycle 4 (21-day cycles).

  7. Area Under the Concentration Time Curve (AUC) for HWK-007 (ADC, total antibody, CPT116, and CPT119)

    The total area under the concentration time curve of study drug and drug components following infusion.

    Time frame: Cycle 1 and Cycle 4 - (21-day cycles)

  8. T1/2 - Half-life of HWK-007 (ADC, total antibody, CPT116, and CPT119)

    Time for 1/2 of the infused drug to be eliminated/metabolized

    Time frame: Cycle 1 and Cycle 4 (21-day cycles)

  9. Clearance (CL)

    Measured rate at which HWK-007 is cleared from the blood following infusion.

    Time frame: Cycle 1 and Cycle 4 (21-day cycles)

  10. Evaluate the Duration of Response (DoR) to HWK-007

    Measure the time from evidence of response by CT-scan until evidence of progression of cancer.

    Time frame: From Cycle 1, Day 1 (21-day cycles) until disease progression or 24 months, whichever comes first.

  11. Evaluate Progression-free Survival (PFS)

    Measure the time from the first infusion of HWK-007 until evidence of cancer progression is detected.

    Time frame: From Cycle 1, Day 1 (21-day cycles) infusion to End of Study (up to 24 months)

  12. Evaluate Disease control Rate (DCR)

    Measure the time from Cycle 1, Day 1 that cancer does not worsen by RECIST1.1 criteria.

    Time frame: From Cycle 1, Day 1 (21-day cycles) until disease progression or 24 months, whichever comes first.

  13. Time to Response (TTR)

    Time from Cycle 1, Day 1 infusion of HWK-007 until evidence of response via CT scan according to RECIST1.1 criteria.

    Time frame: From Cycle 1, Day 1 (21-day cycles) until End of Study or 24 months, whichever comes first.

07

Study locations

10 of 12 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes

Supporting information: Clinical study report

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Oct 2028, 34 months after the start.

Of 88 industry-sponsored phase 1 interventional studies under Endometrial Neoplasms, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 69. This study's planned 34 months is below that.

Counting every sponsor, half of 131 studies reached it within 61 months; a quarter within 46 and three quarters within 79.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2026
First posted
Mar 3, 2026
StartActual
Dec 19, 2025
Primary completionEst.
Oct 2028
CompletionEst.
Dec 2028
Last update
Aug 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07444814
Lead sponsor
Whitehawk Therapeutics, Inc.
Responsible party
Sponsor
First posted
Mar 3, 2026
Start date
Dec 19, 2025
Primary completion
Oct 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Aug 5, 2026

Study contacts

Clinical Trial Manager Lead
Contact
WHWK-Clinical-Trials@whitehawktx.com
866-742-9495
Central email mailbox - Whitehawk Therapeutics
Contact
WHWK-Clinical-Trials@whitehawktx.com
Margaret C Dugan, MD
study director · Whitehawk Therapeutics
Allison Upalawanna
study director · Whitehawk Therapeutics

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion